{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:21:12Z","timestamp":1790238072687,"version":"4.1.0"},"reference-count":39,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:p>Hydroxyurea, indicated for managing sickle cell anemia (SCA), and L\u2010glutamine, indicated for treating sickle cell disease (SCD), were the only pharmacotherapeutic options in this patient population before the approval of crizanlizumab by the U.S. Food and Drug Administration in November 2019 to reduce vaso\u2010occlusive crisis (VOC) frequency. This article reviews the evidence pertaining to crizanlizumab in SCD by searching records in Medline, Embase, and International Pharmaceutical Abstracts. Crizanlizumab, a P\u2010selectin inhibitor, mitigates the microvascular vaso\u2010occlusion in SCD. In the multicenter randomized double\u2010blind SUSTAIN trial, a higher dose of crizanlizumab decreased the incidence of VOCs by 45% and prolonged the median time to the first and second VOC. A post hoc subgroup analysis demonstrated that the proportion of patients who had no VOC incidence during the study period was greater in the crizanlizumab group, and this benefit was consistent regardless of concomitant hydroxyurea use, prior categorized history of VOC frequency, or SCD genotype. Crizanlizumab had a safety profile comparable with placebo. Multiple ongoing clinical trials are trying to establish its roles in pediatric patients with SCD and its effects on alleviating other SCD\u2010related complications. As the first parenteral option for SCD, providers need to formulate administration logistics to improve patients\u2019 access to crizanlizumab. Current available data suggest crizanlizumab is a promising agent to reduce VOC in patients with SCD.<\/jats:p>","DOI":"10.1002\/phar.2409","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T20:45:54Z","timestamp":1588193154000},"page":"535-543","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso\u2010occlusive Pain Crises in Patients with Sickle Cell Disease"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0662-006X","authenticated-orcid":false,"given":"Jin","family":"Han","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice College of Pharmacy University of Illinois at Chicago Chicago Illinois USA"},{"name":"Comprehensive Sickle Cell Center Section of Hematology\/Oncology Department of Medicine University of Illinois at Chicago Chicago Illinois USA"},{"name":"Center for Pharmacoepidemiology and Pharmacoeconomic Research University of Illinois at Chicago Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh L.","family":"Saraf","sequence":"additional","affiliation":[{"name":"Comprehensive Sickle Cell Center Section of Hematology\/Oncology Department of Medicine University of Illinois at Chicago Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor R.","family":"Gordeuk","sequence":"additional","affiliation":[{"name":"Comprehensive Sickle Cell Center Section of Hematology\/Oncology Department of Medicine University of Illinois at Chicago Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904013401307"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510865"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI106273"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198005013021803"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61029-X"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct0708272"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505183322001"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.13.1645"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-419879"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813598"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199806)58:2<117::AID-AJH5>3.0.CO;2-V"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715971"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.052522799"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-498311"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-285718"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23147"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jebm.12141"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.physio.2012.12.001"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611770"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25308"},{"key":"e_1_2_6_23_1","unstructured":"AtagaKI KutlarA DeBonnettL LincyJ KanterJ.Crizanlizumab treatment is associated with clinically significant reductions in hospitalization in patients with sickle cell disease: results from the Sustain Study [abstract]. Presented at American Society of Hematology Annual Meeting. Available fromhttps:\/\/ash.confex.com\/ash\/2019\/webprogram\/Paper125868.html.Accessed December 31 2019."},{"key":"e_1_2_6_24_1","doi-asserted-by":"crossref","unstructured":"KanterJ LilesDK Smith\u2010WhitleyK et al.Crizanlizumab 5.0 Mg\/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies. In: American Society of Hematology Annual Meeting. Available:https:\/\/ash.confex.com\/ash\/2019\/webprogram\/Paper123965.html[accessed 31 December 2019]. 2019.","DOI":"10.1182\/blood-2019-123965"},{"key":"e_1_2_6_25_1","unstructured":"LilesD ShahN ScullinB GordeukVR.SUCCESSOR: a multicenter retrospective noninterventional follow\u2010up study in patients with sickle cell pain crises who previously participated in the sustain trial in the United States [abstract]. Presented at the 24th European Hematology Association Congress. Available fromhttps:\/\/library.ehaweb.org\/eha\/2019\/24th\/267436\/darla.liles.successor.a.multicenter.retrospective.noninterventional.follow\u2010up.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D1550%2Aot_id%3D20964%2Amarker%3D530.Accessed March 12 2020."},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30193-9"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904971"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.08.036"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-618587"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-018-1803-3"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01041-7"},{"key":"e_1_2_6_32_1","volume-title":"Endari (L\u2010glutamine) package insert","author":"Emmaus Medical Inc","year":"2017"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.5.16553"},{"key":"e_1_2_6_34_1","volume-title":"Adakveo (crizanlizumab) [package insert]","author":"Novartis Pharmaceuticals Corporation","year":"2019"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903212"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21968"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27721"},{"key":"e_1_2_6_38_1","first-page":"419","article-title":"Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta\u2010analysis","volume":"7","author":"Srivastava K","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-583351"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14303"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.2409","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2409","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2409","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:35:25Z","timestamp":1761042925000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1002\/phar.2409"],"URL":"https:\/\/doi.org\/10.1002\/phar.2409","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,20]]},"assertion":[{"value":"2020-05-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}